• LAST PRICE
    16.1200
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    16.1000/ 22
  • Ask / Lots
    17.9000/ 1
  • Open / Previous Close
    0.0000 / 16.1200
  • Day Range
    ---
  • 52 Week Range
    Low 12.9500
    High 25.4700
  • Volume
    5
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • May 24, 2024

      Show headlines and story abstract
    • 4:35PM ET on Friday May 24, 2024 by Dow Jones
      Companies Mentioned: RCUS
      HAYWARD, Calif.--(BUSINESS WIRE)--May 24, 2024--
      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 16,300 shares of the Company's common stock at an exercise price per share of $16.28, which was the closing price on May 23, 2024, and restricted stock units to acquire a total of 8,150 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.
    • 4:35PM ET on Friday May 24, 2024 by Business Wire
      Companies Mentioned: RCUS

      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 16,300 shares of the Company's common stock at an exercise price per share of $16.28, which was the closing price on May 23, 2024, and restricted stock units to acquire a total of 8,150 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.

  • May 9, 2024

      Show headlines and story abstract
    • 4:35PM ET on Thursday May 09, 2024 by Dow Jones
      Companies Mentioned: RCUS
      HAYWARD, Calif.--(BUSINESS WIRE)--May 09, 2024--
      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted 17 new employees options to purchase a total of 141,100 shares of the Company's common stock at an exercise price per share of $15.26, which was the closing price on May 8, 2024, and restricted stock units to acquire a total of 70,555 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.
    • 4:35PM ET on Thursday May 09, 2024 by Business Wire
      Companies Mentioned: RCUS

      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted 17 new employees options to purchase a total of 141,100 shares of the Company's common stock at an exercise price per share of $15.26, which was the closing price on May 8, 2024, and restricted stock units to acquire a total of 70,555 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.

    • 9:00AM ET on Thursday May 09, 2024 by Dow Jones
      Companies Mentioned: RCUS

      Ratings actions from Benzinga: https://www.benzinga.com/quote/RCUS/analyst-ratings

      (END) Dow Jones Newswires

      May 09, 2024 09:00 ET (13:00 GMT)

Peers Headlines